Scientific Poster Session IV: Students Research-in-Progress

Students Research in Progress
  Tuesday, November 14, 2023
  08:30 AM–10:00 AM

Abstract

Introduction: Long-acting injectable Cabenuva (generic cabotegravir and rilpivirine, CAB/RPV) administered every 4 weeks demonstrated non-inferiority to oral antiretroviral therapy (ART) in a phase 3 clinical trial regarding virologic suppression maintenance for HIV-1 infection treatment. CAB/RPV became available to patients at Cleveland Clinic Main Campus in September 2021.

Research Question or Hypothesis: Is CAB/RPV able to maintain viral suppression in patients previously suppressed on oral ART for treatment of HIV infection?

Study Design: This was a retrospective, single-center, chart review including patients who received at least one dose of CAB/RPV.

Methods: Patient demographics, reason for switch, insurance, and laboratory tests were collected. The primary endpoint evaluated Cabenuva’s efficacy in maintaining viral suppression in patients previously suppressed on oral ART. Secondary endpoints analyzed patients that missed Cabenuva doses and viral suppression maintenance following missed doses. Results were summarized using descriptive statistics.

Results: Of 42 participants that received at least one dose of Cabenuva, most were male (91%), median age was 42 years, and 39 patients (93%) received combination nucleoside reverse transcriptase inhibitor and integrase inhibitor before CAB/RPV. Of 42 participants that received at least one dose of CAB/RPV, 88% maintained a viral load below 50 copies/mL at most recent follow-up since CAB/RPV initiation with median 3.6 months follow-up time (IQR of 1-3). Additionally, 2% had a viral load over 50 copies/mL (52.4 and 107 copies/mL), and 10% did not receive viral load assessments since starting CAB/RPV. Ten participants received their CAB/RPV dose outside the approved window with median 4 days outside the window (IQR 1-4). Eight participants (80%) remained virologically suppressed after a missed dose, and the remaining 20% were not reassessed. Further results are in progress.

Conclusion: CAB/RPV achieved maintenance of viral suppression in participants previously suppressed on oral ART, which was sustained even after missed doses in most cases.

Presenting Author

Aaron Twardzik Bachelor of Science in Pharmaceutical Sciences
The Cleveland Clinic

Authors

Andrea Pallotta PharmD, BCPS, BCIDP, AAHIVP
Cleveland Clinic

Ramara Walker PharmD, BCIDP, AAHIVP
The Cleveland Clinic